You are here: Home: Audio Program Guide: CCU 4 | 2006 Audio
 
  Go to interview with Mace Rothenberg, MD
Go to interview with Nicholas J Petrelli, MD
Go to interview with Paulo M Hoff, MD
Go to interview with Steven R Alberts, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Mace Rothenberg, MD
Ingram Professor of Cancer Research
Director of Phase One Drug Development
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Recent trends in colorectal cancer clinical research
Track 3 Combining bevacizumab/cetuximab plus chemotherapy
Track 4 Multimodality therapeutic approach to patients with hepatic-only disease
Track 5 Role of aggressive surveillance in earlier detection of recurrent disease
Track 6 Adjuvant therapy for patients with Stage II/III colon cancer
Track 7 Clinical implications of the X-ACT adjuvant trial comparing capecitabine to 5-FU/LV
Track 8 Dosing capecitabine in the adjuvant setting
Track 9 Substitution of capecitabine for 5-FU in combination with oxaliplatin
Track 10 Current generation of adjuvant trials in colon cancer
Track 11 Potential side effects of biologic agents in the adjuvant setting
Track 12 Oxaliplatin-associated neurotoxicity
Track 13 Advances in the treatment of rectal cancer
Track 14 Incorporation of capecitabine and oxaliplatin into neoadjuvant trials in rectal cancer
Track 15 Clinical and research developments in colorectal cancer presented at ASCO 2006
Nicholas J Petrelli, MD
IProfessor of Surgery
Thomas Jefferson University
Philadelphia, Pennsylvania
Medical Director
Helen F Graham Cancer Center
Newark, Delaware
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Evaluating resectability of hepatic metastases
Track 3 Utility of radiofrequency ablation for hepatic metastases
Track 4 NSABP-C-09: CAPOX with hepatic arterial infusion of FUDR versus CAPOX for patients with resected or ablated hepatic metastases
Track 5 Quality control among surgical oncologists treating colon cancer
Track 6 Combined-modality preoperative chemoradiation therapy for rectal cancer
Track 7 Clinical evaluation and staging of rectal cancer
Track 8 Evaluation of patient suitability for abdominal perineal resection
Track 9 NSABP-R-04: Preoperative radiation therapy and capecitabine with or without oxaliplatin or continuous infusion 5-FU with or without oxaliplatin in rectal cancer
Track 10 Surgical considerations in open versus laparoscopic colectomy
Track 11 Factors related to the adequacy of nodal sampling
Track 12 Multimodality management of early colon cancer
Track 13 NSABP-C-10 trial for patients with synchronous primary and metastatic disease
Track 14 Treatment of patients presenting with both primary and resectable metastatic disease
Paulo M Hoff, MD
Executive Director
Hospital Sirio Libanes
São Paulo, Brazil
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 MD Anderson study of FOLFIRI with bevacizumab
Track 3 Effects of bevacizumab on tumor blood flow
Track 4 Clinical implications of the MD Anderson FOLFIRI/bevacizumab study
Track 5 Selection of first-line therapy for chemotherapy-naïve patients
Track 6 Treatment after discontinuation of oxaliplatin due to neurotoxicity followed by progression on bevacizumab
Track 7 MD Anderson retrospective analysis of patients treated with bevacizumab
Track 8 Effects of bevacizumab on wound healing and bowel perforation
Track 9 AVANT adjuvant study comparing FOLFOX to FOLFOX or CAPOX with bevacizumab
Track 10 Ongoing adjuvant trials in colon cancer: NCCTG-N0147 and NSABP-C-08
Track 11 MD Anderson preoperative study of capecitabine/bevacizumab with radiation therapy
Steven R Alberts, MD
Associate Professor of Oncology
Mayo Clinic College of Medicine
Rochester, Minnesota
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Adjuvant therapy for patients with Stage II colon cancer
Track 3 Relative contraindications to the use of adjuvant oxaliplatin
Track 4 Use of adjuvant fluoropyrimidine monotherapy
Track 5 Use of adjuvant irinotecan-containing regimens
Track 6 Increasing resectability of hepatic metastases
Track 7 Incorporation of biologic therapies into neoadjuvant chemotherapy regimens
Track 8 Background and rationale for the NSABP-C-09 study of capecitabine, oxaliplatin and FUDR
Track 9 Achieving durable control or cure in patients with hepatic metastases
Track 10 Rationale for incorporation of capecitabine and oxaliplatin into NSABP-C-09
Track 11 Side effects and tolerability of CAPOX and intrahepatic FUDR
Track 12 Radiofrequency ablation in the treatment of hepatic metastases
Track 13 Advantages of active patient surveillance after adjuvant therapy
Track 14 Treatment of isolated extrahepatic metastases
Track 15 Future directions in clinical research: Targeted and individualized therapy